<DOC>
	<DOCNO>NCT00090194</DOCNO>
	<brief_summary>The purpose study determine IGIV-C , 10 % effective convert donor-recipient crossmatch status positive negative . The crossmatch test use determine donor tissue recipient tissue compatible . The study also evaluate IGIV-C , 10 % allow successful kidney transplantation patient otherwise would able receive transplant . Three dose level IGIV-C , 10 % evaluated determine dose level effective .</brief_summary>
	<brief_title>Improving Transplant Options Highly Sensitized Recipients Using IGIV-C , 10 %</brief_title>
	<detailed_description>Kidney transplantation emerge treatment choice patient end-stage renal disease ( ESRD ) . Preliminary data suggest IGIV therapy could significant benefit modify allograft rejection episode , stabilize long-term allograft function , reduce ischemia/reperfusion injury . Qualified patient in-vitro assessment ability IGIV-C , 10 % convert donor-specific crossmatch ( cytotoxic assay ) positive negative . Those patient successful in-vitro conversion donor-specific crossmatch assay randomize receive IGIV-C , 10 % intravenously dose either 2 gm/kg , 1 gm/kg , 0.5 gm/kg . IGIV-C , 10 % administer 3 5 day prior plan transplantation , transplantation successful , 7 day post-transplant . If receive IGIV-C infusion donor-specific crossmatch reveals cell death fall 20 % less background , crossmatch consider negative . If receive one infusion crossmatch remain positive , additional IGIV-C infusion may administer one-month interval , 4 infusion . A repeat crossmatch must obtain infusion . Patients follow 12 month post-transplant . Concomitant therapy include standard immunosuppression regimen mycophenolate mofetil , tacrolimus , prednisone follow induction therapy thymoglobulin .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Inclusion Criteria Recipient : Endstage renal disease No known contraindication therapy IGIVC , 10 % Have identify live kidney donor Positive crossmatch intend donor Parent guardian willing provide consent , applicable Exclusion Criteria Recipient : Pregnant breastfeed Women childbearing age willing able practice approve method contraception HIV infection Hepatitis B hepatitis C infection History positive tuberculin skin test Selective IgA deficiency , know antiIgA antibody , history severe allergy part clinical trial material Have receive receive multiple organ transplant Any licensed investigational live attenuate vaccine within 2 month screen visit Patients deem unable comply protocol Heart attack within 1 year screen History clinically significant thrombotic episode active peripheral vascular disease Investigational agent within 4 week study entry Inclusion Criteria Donor : Positive donorspecific crossmatch intend recipient ECOG performance status 0 1 Excellent health Acceptable laboratory parameter Compatible blood type Normal heart lung evaluation Parent guardian willing provide consent , applicable</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Transplantation , Homologous</keyword>
	<keyword>HLA Antigens</keyword>
	<keyword>Autoantibodies</keyword>
	<keyword>Immunoglobulins , Intravenous</keyword>
	<keyword>Living Donors</keyword>
	<keyword>Dose-Response Relationship , Immunologic</keyword>
</DOC>